Biogen and Denali Report the Initiation of P-III (LIGHTHOUSE) Study for BIIB122 to Treat Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Shots:
- The company initiated the patients dosing in the P-III (LIGHTHOUSE) study to evaluate the efficacy and safety profile of BIIB122 vs PBO in ~400 patients with Parkinson’s disease and a confirmed pathogenic mutation in the LRRK2 gene. The therapy is being co-develop and co-commercialized by Denali and Biogen
- The 1EPs of the study are a time to confirm worsening as assessed by using MDS-UPDRS over the treatment period for ~180wks.
- BIIB122 is a selective, CNS-penetrant small molecule inhibitor of LRRK2 that improves lysosomal dysfunction. BIIB122 is intended to affect the underlying biology and reduce the progression of Parkinson's disease
Ref: Biogen | Image: Biogen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
